Tislelizumab-jsgr received its first FDA approval to treat certain esophageal cancers. The U.S. Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra) for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who...
Why do many Asian American women who have never smoked have lung cancer, and a report finds acne products can create cancer-causing benzine.
A new treatment regimen that includes a Bruton’s tyrosine kinase inhibitor was approved for follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanubrutinib (Brukinsa) in combination with obinutuzumab...
First-line nivolumab with chemotherapy was approved for bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of patients with unresectable...
The FDA has approved inotuzumab ozogamicin for pediatric patients with certain leukemias. The U.S. Food and Drug Administration (FDA) has approved inotuzumab ozogamicin (Besponsa) for the treatment of pediatric patients aged 1 year or...
The FDA has approved amivantamab-vmjw, both alone and in combination with chemotherapy, for the treatment of certain non-small cell lung cancers. The U.S. Food and Drug Administration (FDA) has approved amivantamab-vmjw (Rybrevant), in combination...
February’s selections include a modified Zika virus to treat cancer, insights into treatment resistance, and more.
Melanoma drug becomes first cell therapy approved to treat a solid tumor, and a new method for treating mesothelioma extended patient survival in a recent trial.
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.
The FDA has approved osimertinib plus chemotherapy for non-small cell lung cancer with EGFR mutations. The U.S. Food and Drug Administration (FDA) has approved osimertinib (Tagrisso) plus platinum-based chemotherapy for the treatment of patients...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More